Rimegepant orally disintegrating tablets in the acute treatment of migraine: a profile of their use

Declarations

Funding The preparation of this review was not supported by any external funding.

Authorship and conflict of interest E. Kim is a contracted employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of interest. K.A. Lyseng-Williamson is the Editor of Drugs & Therapy Perspectives, was not involved in any publishing decisions for this manuscript, and is a salaried employee of Adis International Limited/Springer Nature. She has no other conflicts of interest to declare. All authors contributed to the review and are responsible for the article content.

Ethics approval, consent to participate, consent for publication, availability of data and material, code availability Not applicable.

Additional information about this Adis Drug Review can be found here

Abstract

Rimegepant orally disintegrating tablets (ODT) for sublingual or oral use (Nurtec™ ODT) are a valuable option for the acute treatment of migraine ± aura in adults, especially those with contraindications, treatment failure, or tolerability issues with triptans. Rimegepant is a calcitonin gene-related peptide (CGRP) receptor antagonist, and is the first, and currently only, drug in this class available as an ODT formulation in the USA. A single sublingual dose of rimegepant ODT 75 mg provided freedom from pain, freedom from the most bothersome migraine symptoms (e.g., nausea, phonophobia, photophobia), and freedom from functional disability at 2-h post dose relative to placebo in adults with a migraine attack with pain of moderate or severe intensity ± aura. Beneficial effects on migraine were provided as early as 1-h post dose,) and were sustained for 2–48 h. Rimegepant ODT was well tolerated, with a tolerability profile similar to that of placebo, with no reports of serious, cardiovascular, or hepatic adverse events in patients with migraine.

© Springer Nature Switzerland AG 2020